Inhibikase Cleared to Expand Phase 1 IkT-148009 Study

Inhibikase Cleared to Expand Phase 1 IkT-148009 Study

300878

Inhibikase Cleared to Expand Phase 1 IkT-148009 Study

Inhibikase Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to start a Phase 1 clinical trial evaluating its investigational, once-daily, oral medicine IkT-148009 in patients with Parkinson’s disease. The clearance comes after the agency reviewed the safety, tolerability and pharmacokinetic data from a Phase 1 study in healthy volunteers. Pharmacokinetics refers to how a compound moves into, through, and out of the body. “The extension of our Phase 1 study of IkT-148009 for the treatment…

You must be logged in to read/download the full post.